Description of Medical ServiceC1 Esterase Inhibitor (C1-INH) concentrate is proposed for inclusion on the National Products and Services List (NPSL) for the management of patients with a confirmed diagnosis of Hereditary angioedema (HAE) Type I or II. Administration of human C1-INH to patients with HAE Type I or II replaces the missing or malfunctioning C1-INH protein resulting in relief from the symptoms of HAE.
Description of Medical ConditionHereditary angioedema (HAE) is an autosomal dominant disorder characterised by recurrent subcutaneous and submucosal oedema without urticaria. One or more of various peripheral or central areas can be affected during an acute HAE attack, with laryngeal swelling the most serious as it may be fatal.
Reason for ApplicationNew non-MBS item
Medical Service TypeTherapeutic
Previous Application NumberNot Applicable
PICO ConfirmationPDF Version Unratified Draft Protocol for Consultation (PDF 978 KB)
Word Version Unratified Draft Protocol for Consultation (Word 1094 KB)
PDF Version Feedback and Survey Form (PDF 31 KB)
Word Version Feedback and Survey Form (Word 48 KB)
Final Protocol (PDF 1029 KB)
Final Protocol (Word 1101 KB)
Public Summary DocumentPublic Summary Document (PDF 942 KB)
Public Summary Document (Word 191 KB)